TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $144.25.

A number of equities research analysts have commented on TMDX shares. Wall Street Zen raised shares of TransMedics Group from a “hold” rating to a “buy” rating in a research report on Sunday, December 28th. Jefferies Financial Group assumed coverage on TransMedics Group in a report on Monday, October 13th. They issued a “buy” rating and a $145.00 price objective for the company. Piper Sandler reiterated an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Needham & Company LLC raised their target price on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Finally, Canaccord Genuity Group upped their price target on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, CFO Gerardo Hernandez sold 920 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the transaction, the chief financial officer directly owned 15,064 shares in the company, valued at approximately $2,103,235.68. This trade represents a 5.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David Weill sold 5,000 shares of TransMedics Group stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the transaction, the director owned 12,134 shares in the company, valued at $1,682,257.76. This represents a 29.18% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 8,920 shares of company stock valued at $1,257,310. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently bought and sold shares of TMDX. Whittier Trust Co. of Nevada Inc. increased its position in TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after buying an additional 206 shares in the last quarter. Salomon & Ludwin LLC bought a new position in shares of TransMedics Group during the 3rd quarter valued at approximately $28,000. Harvest Fund Management Co. Ltd bought a new position in shares of TransMedics Group during the 3rd quarter valued at approximately $29,000. Allworth Financial LP increased its holdings in TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares in the last quarter. Finally, Optiver Holding B.V. raised its stake in TransMedics Group by 248.1% during the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after acquiring an additional 191 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $138.49 on Wednesday. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The firm has a market cap of $4.73 billion, a price-to-earnings ratio of 56.07 and a beta of 2.03. The business has a 50-day simple moving average of $133.78 and a two-hundred day simple moving average of $123.25. TransMedics Group has a fifty-two week low of $60.46 and a fifty-two week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. The firm had revenue of $143.82 million during the quarter, compared to analyst estimates of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business’s revenue for the quarter was up 32.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.12 earnings per share. On average, analysts expect that TransMedics Group will post 1 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.